MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials

Reuters03:00

MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials

MoonLake Immunotherapeutics released Week 40 data from Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing responses continued to strengthen over time.
Pooled Week 40 results showed 62% of treated patients achieved HiSCR75, with up to 32% reaching HiSCR100.
Lesion-level analysis showed up to 25% achieved inflammatory remission at Week 40, defined as complete clearance of abscesses, nodules, draining tunnels.
Patient-reported outcomes improved, with up to 43% reporting at least 3-point improvement in worst skin pain score, while 65% posted at least 4-point improvement in DLQI.
Data were scheduled for presentation later on March 28 at 2026 American Academy of Dermatology Annual Meeting; MoonLake also guided to 52-week VELA data in Q2 2026, with BLA submission for HS targeted in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281500PRIMZONEFULLFEED1001172804) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623338889?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-29 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623338889","market":"fut","top_or_hot":-1,"title":"MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> released Week 40 data from Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing responses continued to strengthen over time.\n        </li>\n<li>\n          Pooled Week 40 results showed 62% of treated patients achieved HiSCR75, with up to 32% reaching HiSCR100.\n        </li>\n<li>\n          Lesion-level analysis showed up to 25% achieved inflammatory remission at Week 40, defined as complete clearance of abscesses, nodules, draining tunnels.\n        </li>\n<li>\n          Patient-reported outcomes improved, with up to 43% reporting at least 3-point improvement in worst skin pain score, while 65% posted at least 4-point improvement in DLQI.\n        </li>\n<li>\n          Data were scheduled for presentation later on March 28 at 2026 American Academy of Dermatology Annual Meeting; MoonLake also guided to 52-week VELA data in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, with BLA submission for HS targeted in H2 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281500PRIMZONEFULLFEED1001172804) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-29 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> released Week 40 data from Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing responses continued to strengthen over time.\n        </li>\n<li>\n          Pooled Week 40 results showed 62% of treated patients achieved HiSCR75, with up to 32% reaching HiSCR100.\n        </li>\n<li>\n          Lesion-level analysis showed up to 25% achieved inflammatory remission at Week 40, defined as complete clearance of abscesses, nodules, draining tunnels.\n        </li>\n<li>\n          Patient-reported outcomes improved, with up to 43% reporting at least 3-point improvement in worst skin pain score, while 65% posted at least 4-point improvement in DLQI.\n        </li>\n<li>\n          Data were scheduled for presentation later on March 28 at 2026 American Academy of Dermatology Annual Meeting; MoonLake also guided to 52-week VELA data in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, with BLA submission for HS targeted in H2 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281500PRIMZONEFULLFEED1001172804) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDLbYhcY2:1","article_id":"2623338889","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623338889","pubTimestamp":1774724421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MoonLake Immunotherapeutics released Week 40 data from Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing responses continued to strengthen over time.Pooled Week 40 results showed 62% of treated patients achieved HiSCR75, with up to 32% reaching HiSCR100.Lesion-level analysis showed up to 25% achieved inflammatory remission at Week 40, defined as complete clearance of abscesses, nodules, draining tunnels.Patient-reported outcomes improved, with up to 43% reporting at least 3-point improvement in worst skin pain score, while 65% posted at least 4-point improvement in DLQI.Data were scheduled for presentation later on March 28 at 2026 American Academy of Dermatology Annual Meeting; MoonLake also guided to 52-week VELA data in Q2 2026, with BLA submission for HS targeted in H2 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","MLTX":"MoonLake Immunotherapeutics"},"translate_title":"MoonLake sonelokimab在3期HS试验第40周达到62%HiSCR75","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":0.9,"NDAQ":0.9},"content_text":"MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials\n    \n\n\nMoonLake Immunotherapeutics released Week 40 data from Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing responses continued to strengthen over time.\n        \n\n          Pooled Week 40 results showed 62% of treated patients achieved HiSCR75, with up to 32% reaching HiSCR100.\n        \n\n          Lesion-level analysis showed up to 25% achieved inflammatory remission at Week 40, defined as complete clearance of abscesses, nodules, draining tunnels.\n        \n\n          Patient-reported outcomes improved, with up to 43% reporting at least 3-point improvement in worst skin pain score, while 65% posted at least 4-point improvement in DLQI.\n        \n\n          Data were scheduled for presentation later on March 28 at 2026 American Academy of Dermatology Annual Meeting; MoonLake also guided to 52-week VELA data in Q2 2026, with BLA submission for HS targeted in H2 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281500PRIMZONEFULLFEED1001172804) on March 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623338889","isCrawlerRequest":true}